Two Phase III trials to study remdesivir in COVID-19 patients initiated
Gilead Sciences has announced that two Phase III studies to test the safety and efficacy of remdesivir in COVID-19 patients have begun.
List view / Grid view
Gilead Sciences has announced that two Phase III studies to test the safety and efficacy of remdesivir in COVID-19 patients have begun.
The FDA and EMA have announced which COVID-19 treatments and vaccines are currently in development, as well as how they are supporting clinical trials.
Gilead Sciences say they are confident they can maintain an expedited regulatory review timeline for remdesivir as a treatment for COVID-19 without Orphan Drug Designation (ODD).
As the world rushes to identify the best coronavirus treatments and vaccines, John Cahill rounds up the latest developments in potential COVID-19 therapies.
The US NIH has initiated a clinical trial for remdesivir and two pharmaceutical companies will work together to manufacture antibody treatments to tackle the coronavirus.